Deep Dive: Accretion/Dilution Analysis Explained

Accretion/dilution analysis answers one question: after the deal closes, will the combined company earn more or less per share than the acquirer earned on its own?

Accretive deal: Pro forma EPS is higher than the acquirer's standalone EPS. This happens when the target's earnings yield (earnings divided by price paid) exceeds the acquirer's after-tax cost of financing. Each share now represents a claim on more earnings.

Dilutive deal: Pro forma EPS is lower. This occurs when the acquirer overpays relative to the target's earnings power, or when financing costs (interest on new debt or shares issued) exceed what the target contributes.

The arithmetic is unforgiving. If Company A earns $5.00 per share before acquiring Company B, and pro forma combined EPS drops to $4.50, the deal is 10% dilutive. If pro forma EPS rises to $5.50, the deal is 10% accretive. The market typically reacts in the same direction within minutes of an announcement.

But accretion does not equal value creation. Microsoft's $69 billion acquisition of Activision Blizzard was dilutive in Year 1 and turned into one of the highest-return deals of the decade — Game Pass subscribers and mobile gaming reach were never going to show up in the first earnings model. Conversely, deals can be made accretive through financial engineering — buybacks funded by target cash flow, aggressive purchase price allocation, cherry-picked synergy targets — while quietly destroying long-term value. Accretion is necessary for a good deal but never sufficient.

The professional framework simplifies to six steps, with one worked example at the end using current 2026 rate data:

Step 1: Calculate the acquirer's standalone EPS. Net income divided by shares outstanding. If the acquirer earns $10 billion with 2 billion shares, standalone EPS is $5.00.

Step 2: Determine the financing structure. Three main methods:

• All cash (existing cash or new debt): cost = after-tax interest expense
• All stock (new shares issued to target shareholders): cost = dilution from share count increase
• Mixed (most common for deals over $10 billion): apply both adjustments proportionally

Step 3: Calculate the target's earnings contribution. Target net earnings, adjusted for non-recurring items and credible synergies (discount management's number — see Section 5).

Step 4: Account for financing costs. With investment-grade corporate borrowing at 5.3-5.7% in April 2026 (10-year Treasury at 4.36% plus a 100-130 bp credit spread for A/BBB rated issuers), each $1 billion of debt financing costs roughly $55 million annually pre-tax, or about $41 million after tax at the 21% federal corporate rate plus state taxes.

Step 5: Calculate pro forma EPS.

Pro Forma EPS = (Acquirer Net Income + Target Net Income − Financing Costs + Synergies) ÷ (Acquirer Shares + New Shares Issued)

Step 6: Compare and interpret. If pro forma EPS is greater than standalone EPS, the deal is accretive. The percentage difference tells you the magnitude. Most accretion claims fall in the 2-7% range; anything claimed above 10% in Year 1 deserves scrutiny.

Worked example. Acquirer: $10B net income, 2B shares ($5.00 EPS). Target: $1B net income, all-cash purchase at $20B (20x P/E). Debt-financed at 5.5% pre-tax = $1.1B interest, or $869M after tax. Synergies: $200M after tax (Year 1). Pro forma EPS = ($10B + $1B − $869M + $200M) ÷ 2B = $5.17. That is 3.4% accretive. At 7% borrowing costs (the 2024 environment), the same deal: ($10B + $1B − $1.1B + $200M) ÷ 2B = $5.05 — barely accretive. The 150 bps of rate relief turned a marginal deal into a clearly accretive one without changing anything about the businesses.

Five variables determine the outcome. The first two account for roughly 80% of the variance in real deals:

1. The relative P/E ratio (the dominant driver). When a high-P/E company acquires a low-P/E target, the deal is almost always accretive in Year 1 — the acquirer's expensive stock can buy proportionally more earnings. The reverse is nearly always dilutive. Microsoft (28x P/E) acquiring small SaaS companies at 15-18x is structurally accretive before synergies. Disney (18x) buying entertainment assets at 22x is structurally dilutive before synergies. The rule of thumb: in an all-stock deal, if the target's P/E (including premium paid) exceeds the acquirer's P/E, the deal is dilutive.

2. The acquisition premium. Public-market deals typically clear at a 25-40% premium to the unaffected stock price. Bidding wars push that higher — the Paramount-Warner Bros. Discovery contest with Netflix pushed the implied premium past 50%. Each 10 percentage points of additional premium translates to roughly 1.5-2.5% of additional Year 1 dilution before synergies, depending on financing structure.

3. The cost of debt financing. With the fed funds rate at 3.64% and the 10-year Treasury at 4.36% (April 2026), investment-grade corporate borrowing rates sit at roughly 5.3-5.7%. That is materially lower than the 6.5-7.5% that prevailed in late 2023 and 2024. The math is straightforward: every 100 basis points of rate compression on $10 billion of debt financing improves pro forma earnings by about $74 million after tax — enough to flip many marginal deals from dilutive to accretive without any operational improvement.

4. Expected synergies. Companies project cost savings from eliminating duplicate functions, consolidating facilities, and combined purchasing power. The market is right to be sceptical: studies from McKinsey and BCG consistently show companies achieve only 50-70% of announced synergies, and timing slips by 50-100% versus initial guidance. A useful filter: discount management's synergy number by 35% before running your own accretion math.

5. Tax treatment and deal structure. Asset purchases versus stock purchases trigger different tax consequences. Asset deals can deliver a stepped-up tax basis that shields earnings for years (Section 338(h)(10) elections); stock deals usually cannot. The difference can swing pro forma earnings by 3-8% on cross-border or PE-style deals.

The interplay between these variables means the same target can be accretive to one acquirer and dilutive to another, depending on relative valuations, financing capacity, and synergy capture potential. There is no universal answer — only the math after you plug in the specific numbers.

Three case studies that illustrate the framework's strengths and the patterns that repeat:

Microsoft-Activision ($69 billion, 2023) — Initially dilutive, strategically vindicated. Microsoft paid roughly 30x Activision's trailing earnings, far above its own ~28x multiple, making the deal Year 1 dilutive. The thesis was never about EPS — it was about Game Pass subscriber acceleration, mobile reach via Candy Crush, and exclusive content that would have taken a decade to build internally. By Year 3, Activision's earnings contribution plus Game Pass subscriber growth made the deal accretive. The lesson: when the strategic logic is genuinely transformational and the acquirer has the balance sheet to absorb short-term dilution, the EPS optics in Year 1 are noise.

Capital One-Discover ($35.3 billion, completed 2024) — Accretive on Day 1. Capital One acquired Discover at roughly 12x earnings versus its own 11x multiple — a setup where the relative P/E spread was nearly neutral but the network effects (Discover's payment rails) added roughly $1.2 billion in projected annual synergies. The deal was modestly accretive in Year 1 even before synergies, and significantly accretive once the network monetisation began in 2025. The lesson: deals where the financial math and strategic logic both point the same direction are the most reliable accretion candidates.

AB InBev-SABMiller ($107 billion, 2016) — Accretive through cost synergies, with a hangover. AB InBev paid a 50% premium that initially made the deal dilutive. The cost-cutting culture delivered over $3 billion in annual synergies — exceeding initial projections — and the deal turned accretive within two years. But the $108 billion of resulting debt left AB InBev capital-constrained for half a decade, forcing a dividend cut and limiting strategic optionality during the craft beer disruption. The lesson: short-term accretion can be bought with leverage, but the bill arrives later.

Accretion/dilution is the headline number, but it has structural blind spots that catch investors flat-footed:

Year 1 myopia. The standard analysis looks 12-24 months out. Amazon's most consequential acquisitions — Whole Foods (2017), MGM (2022) — were both dilutive at announcement and both became foundational. A framework that screened those deals out at the press release would have missed two of the most important strategic moves of the past decade.

Synergy assumptions are systematically inflated. Management has every incentive to project aggressive synergies; nobody gets a deal approved by the board with a model that shows dilution. Empirical research (McKinsey, BCG, multiple academic studies) converges on the same finding: 50-70% of announced synergies are realised, and they take 50-100% longer than projected. A useful adjustment: cut announced synergies by 35% and add 12-18 months to the timing before you decide whether the math still works.

Integration costs are usually buried. Pro forma EPS analyses typically exclude one-time integration costs — restructuring charges, systems integration, severance, regulatory compliance. These often run 5-10% of deal value and reduce actual cash flow even when the deal looks accretive on the model. The Capital One-Discover deal carried roughly $2.7 billion in integration costs spread over 24 months — material against $35 billion of equity value.

EPS itself can be financially engineered. Buybacks funded by target cash flow, aggressive purchase price allocation, cherry-picked synergy projections, and creative treatment of restructuring costs can all push reported EPS higher without changing the underlying economics. Investors should anchor on free cash flow per share, ROIC versus WACC, and net debt trajectory rather than headline pro forma EPS.

What to watch instead. A more complete evaluation combines four lenses: (1) ROIC versus WACC — does the deal generate returns above cost of capital within 3-5 years? (2) Free cash flow per share trajectory — the harder-to-game metric that ultimately drives stock prices. (3) Strategic positioning — does the deal create a defensible moat or just buy revenue? (4) Cultural and operational integration risk — most synergy shortfalls trace back to organisational friction, not strategic miscalculation.

For retail investors, the practical filter is simpler: if a deal is accretive only because of management's high synergy estimates, treat it as dilutive until proven otherwise. If a deal is accretive on the math even with synergies discounted by 35%, the announcement is usually worth taking seriously.